Maria Alvarez-Lopez

Sevilla, AN, Spain

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications

Biomarkers of prognosis and pazopanib response in soft tissue sarcoma: An exploratory analysis.

Biomarkers of prognosis and pazopanib response in soft tissue sarcoma: An exploratory analysis.

Journal: Therapeutic advances in medical oncology
Published: March 17, 2026

Shared germline genomic variants in two patients with double primary gastrointestinal stromal tumours (GISTs).

Shared germline genomic variants in two patients with double primary gastrointestinal stromal tumours (GISTs).

Journal: Journal of medical genetics
Published: May 07, 2024

HMGA1 regulates trabectedin sensitivity in advanced soft-tissue sarcoma (STS): A Spanish Group for Research on Sarcomas (GEIS) study.

HMGA1 regulates trabectedin sensitivity in advanced soft-tissue sarcoma (STS): A Spanish Group for Research on Sarcomas (GEIS) study.

Journal: Cellular and molecular life sciences : CMLS
Published: November 20, 2023

Efficacy of Eribulin Plus Gemcitabine Combination in L-Sarcomas.

Efficacy of Eribulin Plus Gemcitabine Combination in L-Sarcomas.

Journal: International journal of molecular sciences
Published: September 12, 2022

ISG15 as a prognostic biomarker in solitary fibrous tumour.

ISG15 as a prognostic biomarker in solitary fibrous tumour.

Journal: Cellular and molecular life sciences : CMLS
Published: March 02, 2022

Predictive Value of MRP-1 in Localized High-Risk Soft Tissue Sarcomas: A Translational Research Associated to ISG-STS 1001 Randomized Phase III Trial.

Predictive Value of MRP-1 in Localized High-Risk Soft Tissue Sarcomas: A Translational Research Associated to ISG-STS 1001 Randomized Phase III Trial.

Journal: Molecular cancer therapeutics
Published: April 13, 2021

A DNA damage repair gene-associated signature predicts responses of patients with advanced soft-tissue sarcoma to treatment with trabectedin.

A DNA damage repair gene-associated signature predicts responses of patients with advanced soft-tissue sarcoma to treatment with trabectedin.

Journal: Molecular oncology
Published: February 05, 2021

Nivolumab and sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase Ib/II trial.

Nivolumab and sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase Ib/II trial.

Journal: Journal for immunotherapy of cancer
Published: October 19, 2020

Prognostic Impact of let-7e MicroRNA and Its Target Genes in Localized High-Risk Intestinal GIST: A Spanish Group for Research on Sarcoma (GEIS) Study.

Prognostic Impact of let-7e MicroRNA and Its Target Genes in Localized High-Risk Intestinal GIST: A Spanish Group for Research on Sarcoma (GEIS) Study.

Journal: Cancers
Published: August 11, 2020

Cancer Stem Cells in Soft-Tissue Sarcomas.

Cancer Stem Cells in Soft-Tissue Sarcomas.

Journal: Cells
Published: May 14, 2020

CUL4A, ERCC5, and ERCC1 as Predictive Factors for Trabectedin Efficacy in Advanced Soft Tissue Sarcomas (STS): A Spanish Group for Sarcoma Research (GEIS) Study.

CUL4A, ERCC5, and ERCC1 as Predictive Factors for Trabectedin Efficacy in Advanced Soft Tissue Sarcomas (STS): A Spanish Group for Sarcoma Research (GEIS) Study.

Journal: Cancers
Published: April 01, 2020

Gene expression analyses determine two different subpopulations in KIT-negative GIST-like (KNGL) patients.

Gene expression analyses determine two different subpopulations in KIT-negative GIST-like (KNGL) patients.

Journal: Oncotarget
Published: July 27, 2017
Showing 1-12 of 12

Last Updated: 09/26/2026